Precision Neuroscience
Develops a brain-computer interface intended to help people with paralysis operate digital devices.
$250MSeries D
ParticipantDF
Duquesne Family Office
Activity from announced rounds
Activity in this selectionSep 30, 2026 · Sep 1, 2026
Duquesne Family Office is the family-office investor identified by Precision Neuroscience and Cellares.
Recorded funding activity
Its recorded company activity also includes Epicrispr’s epigenetic medicines, Ratio’s radiopharmaceuticals and SonoThera’s ultrasound-mediated genetic-medicine delivery. These are separate therapeutic approaches. The institutional record remains distinct from Stanley Druckenmiller’s personal investment identity.
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $750M 2 disclosed · full round size, not this investor’s share